Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
Masaomi Nangaku(The University of Tokyo), Takashi Kadowaki(Toranomon Hospital), Shinya Goto(Tokai University), Hirotaka Watada(Juntendo University), Dan Massey(Taipei Veterans General Hospital), Ryonfa Lee(University of Oxford), Shoichi Maruyama(Nagoya University), Kaitlin J. Mayne, Aiko Tomita(Tokai University), William G. Herrington(Oxford Health NHS Foundation Trust), Sibylle J. Hauske(Heidelberg University), Kohjiro Ueki(Institute for Security Studies), Richard Haynes, Jun Wada(Okayama University), Eitaro Nakashima(Chubu Rosai Hospital), Naoki Kashihara(Kawasaki Medical School)
Cited by 8
Related Papers
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
|Nature Medicine|2002|4.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Adiponectin and Adiponectin Receptors
|Endocrine Reviews|2005|2.6k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k